US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

MBX Biosciences

6.37

-0.6000-8.61%

Post-market: 6.720.3500+5.49%17:16 EDT

Volume:232.30K

Turnover:1.51M

Market Cap:212.91M

PE:-1.09

High:7.15

Open:6.84

Low:6.33

Close:6.97

Loading ...

Overview Company News Filings

MBX Biosciences, Inc.: Promising Outlook with Strong Financials and Key Catalysts

MBX Biosciences Q4 2024 GAAP EPS $(0.47) Beats $(0.59) Estimate, $262.1M In Cash, Cash Equivalents And Marketable Securities As Of December 31, 2024; Expected To Support Operations Into Mid-2027

Mbx Biosciences Inc: Qtrly Loss per Share $0.47

THOMSON REUTERS

MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Microbix Partners with ACPCC to Combat Cervical Cancer in Indo-Pacific

Insider Buyers At MBX Biosciences Likely Disappointed With 17% Slide

Simply Wall St.

BRIEF-MBX Biosciences Announces Additions To Leadership Team

Mbx Biosciences Announces Additions to Leadership Team

THOMSON REUTERS

MBX Biosciences Announces Additions to Leadership Team

BRIEF-Mbx Biosciences Completes Enrollment In Phase 2 Avail Trial Of Mbx 2109 (Canvuparatide) For Hypoparathyroidism

MBX Biosciences completes enrollment in Phase 2 Avail trial of MBX 2109

Mbx Biosciences Completes Enrollment in Phase 2 Avail™ Trial of Mbx 2109 (Canvuparatide) for Hypoparathyroidism

THOMSON REUTERS

MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism

Microbix Hosts Ontario Premier, Showcases Innovations in Life Sciences

‘MBX/HACK the FUN’ Opens Applications: An Acceleration Program for Web3 Game Developers

Microbix Engages Investors at Whistler Capital Event 2025

MBX Biosciences to Participate in March Investor Conferences

Nasdaq Net Change Percentage Gainers & Losers

Stifel Nicolaus Reaffirms Their Buy Rating on MBX Biosciences, Inc. (MBX)

Microbix Biosystems to Release Q1 Fiscal 2025 Results and Host Webinar

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MBX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MBX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MBX\",,,,,undefined,":{"symbol":"MBX","market":"US","secType":"STK","nameCN":"MBX Biosciences","latestPrice":6.37,"timestamp":1743710400000,"preClose":6.97,"halted":0,"volume":232296,"hourTrading":{"tag":"盘后","latestPrice":6.72,"preClose":6.37,"latestTime":"17:16 EDT","volume":10934,"amount":69884.103366,"timestamp":1743715004952},"delay":0,"floatShares":13617987,"shares":33424371,"eps":-5.818121,"marketStatus":"Post-Market Trading","change":-0.6,"latestTime":"04-03 19:13:11 EDT","open":6.84,"high":7.15,"low":6.33,"amount":1513684.407648,"amplitude":0.117647,"askPrice":7.45,"askSize":68,"bidPrice":5.63,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-5.818121,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1743724800000},"marketStatusCode":4,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":6.97,"preHourTrading":{"tag":"盘前","latestPrice":7,"preClose":6.97,"latestTime":"06:48 EDT","volume":202,"amount":1453.1399846000002,"timestamp":1743677323370},"postHourTrading":{"tag":"盘后","latestPrice":6.72,"preClose":6.37,"latestTime":"17:16 EDT","volume":10934,"amount":69884.103366,"timestamp":1743715004952},"volumeRatio":0.956068},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MBX\",,,,,undefined,":{"symbol":"MBX","floatShares":13617987,"roa":"-24.17%","roe":"-36.71%","lyrEps":-5.818121,"volumeRatio":0.956068,"shares":33424371,"dividePrice":0,"high":7.15,"amplitude":0.117647,"preClose":6.97,"low":6.33,"week52Low":6.33,"pbRate":"0.83","week52High":27.5,"institutionHeld":0,"latestPrice":6.37,"committee":0.190476,"eps":-5.818121,"divideRate":0,"volume":232296,"delay":0,"ttmEps":-5.818121,"open":6.84,"prevYearClose":18.43,"prevWeekClose":7.76,"prevMonthClose":7.38,"prevQuarterClose":7.38,"fiveDayClose":7.41,"twentyDayClose":10.26,"sixtyDayClose":16.28},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MBX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2520676137","title":"MBX Biosciences, Inc.: Promising Outlook with Strong Financials and Key Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2520676137","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520676137?lang=en_us&edition=fundamental","pubTime":"2025-03-18 20:26","pubTimestamp":1742300802,"startTime":"0","endTime":"0","summary":"Jefferies analyst Michael Yee maintained a Buy rating on MBX Biosciences, Inc. (MBX – Research Report) yesterday and set a price target of $35.00. ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/mbx-biosciences-inc-promising-outlook-with-strong-financials-and-key-catalysts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/mbx-biosciences-inc-promising-outlook-with-strong-financials-and-key-catalysts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX","BK4007"],"gpt_icon":0},{"id":"2520407555","title":"MBX Biosciences Q4 2024 GAAP EPS $(0.47) Beats $(0.59) Estimate, $262.1M In Cash, Cash Equivalents And Marketable Securities As Of December 31, 2024; Expected To Support Operations Into Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2520407555","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520407555?lang=en_us&edition=fundamental","pubTime":"2025-03-17 20:13","pubTimestamp":1742213603,"startTime":"0","endTime":"0","summary":"MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.59) by 20.34 percent. This is a 93.93 percent increase over losses of $(7.74) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44354431/mbx-biosciences-q4-2024-gaap-eps-0-47-beats-0-59-estimate-262-1m-in-cash-cash-equivalents-and-marke","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"MBX Biosciences Q4 2024 GAAP EPS $(0.47) Beats $(0.59) Estimate, $262.1M In Cash, Cash Equivalents And Marketable Securities As Of December 31, 2024; Expected To Support Operations Into Mid-2027","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX"],"gpt_icon":0},{"id":"2520540896","title":"Mbx Biosciences Inc: Qtrly Loss per Share $0.47","url":"https://stock-news.laohu8.com/highlight/detail?id=2520540896","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520540896?lang=en_us&edition=fundamental","pubTime":"2025-03-17 20:03","pubTimestamp":1742212999,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250317:nFWN3Q00PJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MBX"],"gpt_icon":0},{"id":"2520540983","title":"MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2520540983","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520540983?lang=en_us&edition=fundamental","pubTime":"2025-03-17 20:00","pubTimestamp":1742212800,"startTime":"0","endTime":"0","summary":"Enrollment complete in Phase 2 Avail trial of canvuparatide in hypoparathyroidism; topline results on track for Q3 2025 MBX 1416 Phase 2 trial in patients with post-bariatric hypoglycemia expected to ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/17/3043631/0/en/MBX-Biosciences-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Recent-Corporate-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PBH","MBX","PTH","HP","BK4092"],"gpt_icon":0},{"id":"2520676540","title":"Microbix Partners with ACPCC to Combat Cervical Cancer in Indo-Pacific","url":"https://stock-news.laohu8.com/highlight/detail?id=2520676540","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520676540?lang=en_us&edition=fundamental","pubTime":"2025-03-17 19:53","pubTimestamp":1742212424,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Microbix Biosystms ( ($TSE:MBX) ). Microbix Biosystems Inc. has signed a Memorandum of Understanding with the A...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/microbix-partners-with-acpcc-to-combat-cervical-cancer-in-indo-pacific?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/microbix-partners-with-acpcc-to-combat-cervical-cancer-in-indo-pacific?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MBX"],"gpt_icon":0},{"id":"2519839578","title":"Insider Buyers At MBX Biosciences Likely Disappointed With 17% Slide","url":"https://stock-news.laohu8.com/highlight/detail?id=2519839578","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519839578?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:08","pubTimestamp":1741864125,"startTime":"0","endTime":"0","summary":"The recent price decline of 17% in MBX Biosciences, Inc.'s  stock may have disappointed insiders who bought US$534.5k worth of shares at an average price of US$10.69 in the past 12 months. Insiders purchase with the hope of seeing their investments increase in value over time. However, due to recent losses, their initial investment is now only worth US$469.5k, which is not great.While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, logic dictates you should pay some attention to whether insiders are buying or selling shares.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/insider-buyers-mbx-biosciences-likely-110845338.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","MBX"],"gpt_icon":0},{"id":"2517967912","title":"BRIEF-MBX Biosciences Announces Additions To Leadership Team","url":"https://stock-news.laohu8.com/highlight/detail?id=2517967912","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517967912?lang=en_us&edition=fundamental","pubTime":"2025-03-05 21:53","pubTimestamp":1741182827,"startTime":"0","endTime":"0","summary":"BRIEF-MBX Biosciences Announces Additions To Leadership TeamMarch 5 (Reuters) - MBX Biosciences Inc MBX.O:MBX BIOSCIENCES ANNOUNCES ADDITIONS TO LEADERSHIP TEAMSource text: ID:nGNXbhMxkKFurther company coverage: MBX.O (Reuters.Briefs@thomsonreuters.com)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nTUABH0FJQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX","BK4007"],"gpt_icon":0},{"id":"2517919656","title":"Mbx Biosciences Announces Additions to Leadership Team","url":"https://stock-news.laohu8.com/highlight/detail?id=2517919656","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517919656?lang=en_us&edition=fundamental","pubTime":"2025-03-05 21:00","pubTimestamp":1741179601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nTUABH0FJQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MBX","BK4007"],"gpt_icon":0},{"id":"2517919706","title":"MBX Biosciences Announces Additions to Leadership Team","url":"https://stock-news.laohu8.com/highlight/detail?id=2517919706","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517919706?lang=en_us&edition=fundamental","pubTime":"2025-03-05 21:00","pubTimestamp":1741179600,"startTime":"0","endTime":"0","summary":"Chatan Charan, Ph.D. appointed as Senior Vice President, Pharmaceutical Development and CMC. Mark Hope appointed as Senior Vice President, Regulatory and Quality. CARMEL, Ind., March 05, 2025  -- MBX Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointments of Chatan Charan, Ph.D. as Senior Vice President, Pharmaceutical Development and Chemistry, Manufacturing and Controls  and Mark Hope as Senior Vice President, Regulatory and Quality.Chatan Charan, Ph.D. said, “I am excited to join MBX and contribute to the advancement of its innovative peptide portfolio. I’ve been particularly impressed by the Company’s deep scientific foundation and high-potential early-stage candidates and am eager to collaborate with the talented MBX team to bring new therapies to patients in need.”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mbx-biosciences-announces-additions-leadership-130000714.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4092","IE00BHPRN162.USD","LU0971096721.USD","LU0882574139.USD","LU0267386448.USD","BK4006","LU1363072403.SGD","IE00BZ1G4Q59.USD","BK4007","IE00BKVL7J92.USD","LU0170899867.USD","LU0149725797.USD","MBX","BK4120","HP","TISI","PBH","IE00B1BXHZ80.USD","CMC"],"gpt_icon":0},{"id":"2516325631","title":"BRIEF-Mbx Biosciences Completes Enrollment In Phase 2 Avail Trial Of Mbx 2109 (Canvuparatide) For Hypoparathyroidism","url":"https://stock-news.laohu8.com/highlight/detail?id=2516325631","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516325631?lang=en_us&edition=fundamental","pubTime":"2025-03-03 22:17","pubTimestamp":1741011461,"startTime":"0","endTime":"0","summary":"BRIEF-Mbx Biosciences Completes Enrollment In Phase 2 Avail Trial Of Mbx 2109 (Canvuparatide) For HypoparathyroidismMarch 3 (Reuters) - MBX Biosciences Inc MBX.O:MBX BIOSCIENCES COMPLETES ENROLLMENT I","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nTUAB5YRLR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX","BK4007"],"gpt_icon":0},{"id":"2516863683","title":"MBX Biosciences completes enrollment in Phase 2 Avail trial of MBX 2109","url":"https://stock-news.laohu8.com/highlight/detail?id=2516863683","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516863683?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:23","pubTimestamp":1741008197,"startTime":"0","endTime":"0","summary":"MBX Biosciences (MBX) announced the completion of enrollment in its Phase 2 Avail trial of MBX 2109, the Company’s parathyroid hormone peptide prod...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mbx-biosciences-completes-enrollment-in-phase-2-avail-trial-of-mbx-2109?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mbx-biosciences-completes-enrollment-in-phase-2-avail-trial-of-mbx-2109?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MBX"],"gpt_icon":0},{"id":"2516955633","title":"Mbx Biosciences Completes Enrollment in Phase 2 Avail™ Trial of Mbx 2109 (Canvuparatide) for Hypoparathyroidism","url":"https://stock-news.laohu8.com/highlight/detail?id=2516955633","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516955633?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:00","pubTimestamp":1741006805,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nTUAB5YRLR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MBX"],"gpt_icon":0},{"id":"2516633450","title":"MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism","url":"https://stock-news.laohu8.com/highlight/detail?id=2516633450","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516633450?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:00","pubTimestamp":1741006800,"startTime":"0","endTime":"0","summary":"AvailTM trial exceeded enrollment target; topline results expected in Q3 2025. CARMEL, Ind., March 03, 2025  -- MBX Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the completion of enrollment in its Phase 2 Avail trial of MBX 2109 , the Company’s parathyroid hormone  peptide prodrug. Canvuparatide is designed to be long-acting and is in development for the treatment of chronic hypoparathyroidism .About Hypoparathyroidism HP is a rare endocrine disease caused by a deficiency of PTH released by the parathyroid glands that results in decreased calcium levels in the blood leading to hypocalcemia. Hypocalcemia can result in a variety of acute symptoms, such as muscle cramping or spasm, tingling, and neurological symptoms such as depression, confusion and cognitive impairment. More serious complications can occur, including seiz","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mbx-biosciences-completes-enrollment-phase-130000129.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MBX","HP","PTH","BK4092","PBH","BK4007"],"gpt_icon":0},{"id":"2514347337","title":"Microbix Hosts Ontario Premier, Showcases Innovations in Life Sciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2514347337","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514347337?lang=en_us&edition=fundamental","pubTime":"2025-02-28 04:33","pubTimestamp":1740688392,"startTime":"0","endTime":"0","summary":"Microbix Biosystms ( ($TSE:MBX) ) just unveiled an update. Microbix Biosystems Inc. recently hosted Ontario Premier Doug Ford and MPP Deepak Anand ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/microbix-hosts-ontario-premier-showcases-innovations-in-life-sciences?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/microbix-hosts-ontario-premier-showcases-innovations-in-life-sciences?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX","BK4007"],"gpt_icon":0},{"id":"2513559764","title":"‘MBX/HACK the FUN’ Opens Applications: An Acceleration Program for Web3 Game Developers","url":"https://stock-news.laohu8.com/highlight/detail?id=2513559764","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513559764?lang=en_us&edition=fundamental","pubTime":"2025-02-24 08:30","pubTimestamp":1740357033,"startTime":"0","endTime":"0","summary":"seoul, south korea, February 24th, 2025, Chainwire MARBLEX, the web3 gaming ecosystem powered by global gaming giant Netmarble, and Dracoon Venture...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/mbx-hack-the-fun-opens-applications-an-acceleration-program-for-web3-game-developers?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/mbx-hack-the-fun-opens-applications-an-acceleration-program-for-web3-game-developers?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4590","BK4007","FUN","BK4588","HACK","MBX","BK4585","BK4216"],"gpt_icon":0},{"id":"2512190438","title":"Microbix Engages Investors at Whistler Capital Event 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2512190438","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512190438?lang=en_us&edition=fundamental","pubTime":"2025-02-20 02:08","pubTimestamp":1739988530,"startTime":"0","endTime":"0","summary":"The latest update is out from Microbix Biosystms ( ($TSE:MBX) ). Microbix Biosystems Inc. announced its participation in the Whistler Capital Event...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/microbix-engages-investors-at-whistler-capital-event-2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/microbix-engages-investors-at-whistler-capital-event-2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX","ISBC","BK4007","BK4211"],"gpt_icon":0},{"id":"2512818152","title":"MBX Biosciences to Participate in March Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2512818152","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512818152?lang=en_us&edition=fundamental","pubTime":"2025-02-18 21:00","pubTimestamp":1739883600,"startTime":"0","endTime":"0","summary":"CARMEL, Ind., Feb. 18, 2025  -- MBX Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the following investor conferences:. Date: Monday, March 3, 2025Format: Podium Presentation and 1x1 meetingsTime: 10:30 a.m. – 11:00 a.m. ETLocation: Boston, MA. Date: Wednesday, March 12th Format: 1x1 meetingsLocation: Miami Beach, FL","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mbx-biosciences-participate-march-investor-130000976.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PBH","HP","MBX","BK4007","BK4092"],"gpt_icon":0},{"id":"2510819901","title":"Nasdaq Net Change Percentage Gainers & Losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2510819901","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510819901?lang=en_us&edition=fundamental","pubTime":"2025-02-11 06:40","pubTimestamp":1739227200,"startTime":"0","endTime":"0","summary":"Copyright (c) 2025 Dow Jones & Company, Inc.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":[".IXIC","TQQQ","TSYW.SI","LU2210149790.SGD","BK4588","BK4112","BK4585","MNQmain","LU2210150020.SGD","LU2095319765.USD","PSQ","IE00BGHQF748.EUR","IE00B64PRP62.GBP","NVIW.SI","BK4007","QLD","SQQQ","MBX","IE00BKPKM429.USD","NDAQ","NQmain","USJW.SI","USAW.SI","IE00B3QW5Z07.USD","QID"],"gpt_icon":1},{"id":"2510519958","title":"Stifel Nicolaus Reaffirms Their Buy Rating on MBX Biosciences, Inc. (MBX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2510519958","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510519958?lang=en_us&edition=fundamental","pubTime":"2025-02-10 20:45","pubTimestamp":1739191535,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on MBX Biosciences, Inc. (MBX – Research Report) today. The company’s shares closed ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-reaffirms-their-buy-rating-on-mbx-biosciences-inc-mbx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-reaffirms-their-buy-rating-on-mbx-biosciences-inc-mbx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","MBX"],"gpt_icon":0},{"id":"2509786142","title":"Microbix Biosystems to Release Q1 Fiscal 2025 Results and Host Webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2509786142","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509786142?lang=en_us&edition=fundamental","pubTime":"2025-02-06 20:44","pubTimestamp":1738845844,"startTime":"0","endTime":"0","summary":"An announcement from Microbix Biosystms ( ($TSE:MBX) ) is now available. Microbix Biosystems Inc. announced the scheduled release of its Q1 fiscal ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/microbix-biosystems-to-release-q1-fiscal-2025-results-and-host-webinar?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/microbix-biosystems-to-release-q1-fiscal-2025-results-and-host-webinar?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4218","MBX","HST","BK4585","BK4588","BK4181","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":76}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MBX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-17","symbol":"MBX","fiscalQuarterEnding":"2024/12","expectedEps":-0.59,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742184000000,"reportTimeType":"pre","actualEps":-0.47}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MBX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MBX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.75,"buy":0.25,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.75,"analysts":4,"updateTime":1728446400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MBX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MBX","date":"2025-04-02","current":-3.702903,"percent":1,"low":-18.37518,"twenty":-15.748335,"median":-11.182744,"eighty":-6.162773,"high":-3.702903,"avg":-10.638432,"sd":4.407666,"marketCap":229291185},"quantilePoints":[{"date":"2024-09-13","current":-10.797864,"twenty":-10.55484,"median":-10.190304,"eighty":-9.825767,"marketCap":509659168},{"date":"2024-09-20","current":-15.015591,"twenty":-15.168364,"median":-14.852916,"eighty":-11.560463,"marketCap":708735908},{"date":"2024-09-27","current":-17.32133,"twenty":-16.200444,"median":-15.47886,"eighty":-14.65927,"marketCap":817566764},{"date":"2024-10-04","current":-17.328403,"twenty":-17.001639,"median":-15.960592,"eighty":-14.885451,"marketCap":817900601},{"date":"2024-10-11","current":-16.663558,"twenty":-17.001639,"median":-16.288699,"eighty":-15.053784,"marketCap":786519924},{"date":"2024-10-18","current":-16.380645,"twenty":-17.034173,"median":-16.380645,"eighty":-15.256067,"marketCap":773166445},{"date":"2024-10-25","current":-16.366499,"twenty":-17.022857,"median":-16.518565,"eighty":-15.513518,"marketCap":772498771},{"date":"2024-10-31","current":-15.744091,"twenty":-17.017199,"median":-16.373572,"eighty":-15.206557,"marketCap":743121117},{"date":"2024-11-08","current":-14.04827,"twenty":-16.953543,"median":-16.31699,"eighty":-15.206557,"marketCap":775169467},{"date":"2024-11-15","current":-11.803503,"twenty":-16.939398,"median":-16.175534,"eighty":-14.610859,"marketCap":651305476},{"date":"2024-11-22","current":-9.99876,"twenty":-16.932325,"median":-15.949203,"eighty":-13.860717,"marketCap":551721571},{"date":"2024-11-29","current":-12.318278,"twenty":-16.904034,"median":-15.751164,"eighty":-12.256505,"marketCap":679710282},{"date":"2024-12-06","current":-11.682379,"twenty":-16.817745,"median":-15.461179,"eighty":-11.791391,"marketCap":644621993},{"date":"2024-12-13","current":-12.415177,"twenty":-16.690435,"median":-15.206557,"eighty":-11.939161,"marketCap":685057069},{"date":"2024-12-20","current":-12.275885,"twenty":-16.663558,"median":-14.934254,"eighty":-11.791391,"marketCap":677371062},{"date":"2024-12-27","current":-13.256987,"twenty":-16.659314,"median":-14.421446,"eighty":-11.803503,"marketCap":731507280},{"date":"2025-01-03","current":-11.052536,"twenty":-16.546149,"median":-14.047442,"eighty":-11.706604,"marketCap":609867878},{"date":"2025-01-10","current":-8.787523,"twenty":-16.380645,"median":-13.843492,"eighty":-11.523707,"marketCap":484886735},{"date":"2025-01-17","current":-6.383218,"twenty":-16.377816,"median":-13.75965,"eighty":-11.170026,"marketCap":352219585},{"date":"2025-01-24","current":-7.103904,"twenty":-16.366499,"median":-13.256987,"eighty":-10.797864,"marketCap":391986313},{"date":"2025-01-31","current":-7.049398,"twenty":-16.359427,"median":-13.057133,"eighty":-9.859468,"marketCap":388978745},{"date":"2025-02-07","current":-7.424882,"twenty":-16.31699,"median":-12.415177,"eighty":-8.842029,"marketCap":409697544},{"date":"2025-02-14","current":-5.444509,"twenty":-16.309917,"median":-12.318278,"eighty":-7.473331,"marketCap":300422587},{"date":"2025-02-21","current":-7.164466,"twenty":-16.270309,"median":-12.215323,"eighty":-7.193536,"marketCap":395328054},{"date":"2025-02-28","current":-5.947173,"twenty":-16.124609,"median":-12.009413,"eighty":-6.809573,"marketCap":328159044},{"date":"2025-03-07","current":-6.213645,"twenty":-15.986606,"median":-11.803503,"eighty":-6.598818,"marketCap":342862708},{"date":"2025-03-14","current":-5.226487,"twenty":-15.951481,"median":-11.682379,"eighty":-6.524932,"marketCap":288392317},{"date":"2025-03-21","current":-4.302061,"twenty":-15.898279,"median":-11.549143,"eighty":-6.302065,"marketCap":266392236},{"date":"2025-03-28","current":-3.999783,"twenty":-15.778041,"median":-11.258446,"eighty":-6.213645,"marketCap":247674589},{"date":"2025-04-02","current":-3.702903,"twenty":-15.748335,"median":-11.182744,"eighty":-6.162773,"marketCap":229291185}],"updateTime":1743720966944}}}